コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 tandard dose) of total daily energy as a 20% lipid emulsion.
2 ability of phylloquinone from an intravenous lipid emulsion.
3 n containing 10% fish oil or a fish oil-free lipid emulsion.
4 l pressure was observed in rats treated with lipid emulsion.
5 c arrest before and after resuscitation with lipid emulsion.
6 cue of bupivacaine-induced cardiotoxicity by lipid emulsion.
7 shown for this treatment nor for the type of lipid emulsion.
8 esent naturally, in variable amounts, in the lipid emulsion.
9 and avoidance of complications from amended lipid emulsions.
10 r amino acid intakes and fish oil-containing lipid emulsions.
11 rly in low-birth-weight neonates who receive lipid emulsions.
12 a cells without the aid of viral vectors and lipid emulsions.
13 owel mucosa by VV-TPN as opposed to standard lipid emulsions.
14 lic actions compared with available standard lipid emulsions.
15 iled characterization of the in vivo fate of lipid emulsions.
16 ess to bitter-tasting stimuli, as well as to lipid emulsions.
17 (Intralipid) or olive oil-based (ClinOleic) lipid emulsions.
18 of the following 4 different fat emulsions: lipid emulsion 1 (LE1; acid stable, 0.33 mum), lipid emu
19 one patients (81%) received a fish oil-based lipid emulsion (1 g/kg/d), 40 (63%) were weaned, 11 (17%
20 ment with one of the following: intraosseous lipid-emulsion (10 mL/kg over 180 s), intraosseous salin
21 ntraosseous saline (10 mL/kg over 180 s), IV lipid-emulsion (10 mL/kg over 90 s), or no treatment (sh
22 at a similar rate to animals treated with IV lipid emulsion (176 s [152-217 s], p = not significant).
23 pid emulsion 1 (LE1; acid stable, 0.33 mum), lipid emulsion 2 (LE2; acid stable, 52 mum), lipid emuls
24 lipid emulsion 2 (LE2; acid stable, 52 mum), lipid emulsion 3 (LE3; acid unstable, solid fat, 0.32 mu
25 E3; acid unstable, solid fat, 0.32 mum), and lipid emulsion 4 (LE4; acid unstable, liquid fat, 0.38 m
26 d radiolabeled triglyceride derived from the lipid emulsion (a surrogate for chylomicrons; extraction
27 randomized to receive one of three doses of lipid emulsion administered twice in 48 hours or no drug
28 d the fatty acids present in the intravenous lipid emulsion administered: omega-6 linoleic acid (rang
30 n compared to the group that did not receive Lipid Emulsion after bupivacaine overdose (330+/-42 nmol
31 using infusions of a [(3)H]triolein-labeled lipid emulsion and [U-(13)C]oleate during continuous fee
32 nvestigate the metabolism of a n-3 PUFA-rich lipid emulsion and a n-6 PUFA-rich lipid emulsion in a m
33 stricting the dose of parenteral soybean oil lipid emulsion and/or replacing the soybean oil with a p
38 inical reports have led to the acceptance of lipid emulsion as an effective treatment of local anesth
40 rapy, rescues behavioral responsiveness to a lipid emulsion but not to bitter stimuli and that this r
44 ria isolated from rats resuscitated with 20% lipid emulsion compared to the group that did not receiv
45 amics of binding of apoA-I to lipid, we used lipid emulsions composed of triolein (TO) and egg phosph
46 this effect, rats were infused with either a lipid emulsion (consisting mostly of 18:2 fatty acids) o
47 parenteral nutrition prepared either with a lipid emulsion containing 10% fish oil or a fish oil-fre
48 sition and 2) the effect of a multicomponent lipid emulsion containing 30% soybean oil, 30% medium-ch
50 -h fast during infusion of [14C]oleate and a lipid emulsion containing [3H]triolein; the emulsion was
56 ty-enhancing properties of a newly developed lipid emulsion designed for TPN use based on 18-carbon n
57 in which mice are trained to self-administer lipid emulsions directly into the stomach, we show that
64 1) assess the effect on iron absorption of a lipid emulsion given 20 min before or together with an i
65 n erythrocytes 14 d after the test meals.The lipid emulsion given either before or with the meal sign
70 orial in etiology, components of soybean oil lipid emulsions have been implicated in the disease's pa
72 mpared with TPN containing soybean oil-based lipid emulsion (IL-TPN) and fish-oil-based lipid emulsio
73 orida, our objective was to test intravenous lipid emulsion (ILE) as a rapid treatment for brevetoxic
74 and efficacy of a fish oil-based intravenous lipid emulsion (ILE) in the treatment of parenteral nutr
76 ately 0.3 mM) was prevented by infusion of a lipid emulsion in 15 conscious rats (plasma FFA approxim
77 PUFA-rich lipid emulsion and a n-6 PUFA-rich lipid emulsion in a mouse model of TPN and in primary hu
79 otal of 51 patients received olive oil-based lipid emulsion in parenteral nutrition (age 46 +/- 19 yr
85 nts a consensus on the biological aspects of lipid emulsions in parenteral nutrition, emphasizing the
90 0 mg/kg over 20 secs, intravenously) and 20% lipid emulsion infusion (5 mL/kg bolus, and 0.5 mL/kg/mi
95 tion from bupivacaine-induced asystole using lipid emulsion infusion vs. vasopressin, alone and with
97 (-1). min(-1)), and Liposyn (heparinized 10% lipid emulsion) infusions were initiated simultaneously
98 re warranted to optimize this novel route of lipid emulsion injection in emergency situations when in
100 gh-carbohydrate liquid diet plus intravenous lipid emulsion (Intralipid, 4 g fat/kg/d) or intravenous
101 e-Dawley rats into four groups: intraosseous lipid emulsion, intraosseous saline, IV lipid emulsion,
102 oxicity occurs primarily at sodium channels, lipid emulsion is a reasonably well tolerated and effect
103 compressions, and randomized to receive 30% lipid emulsion (L, 5 mL/kg bolus then 1.0 mL/kg/min infu
105 istration of parenteral nutrition, including lipid emulsion (LE), to patients via medical catheters i
108 min, hyperbaric oxygen, insulin, intravenous lipid emulsion, lidocaine, methylene blue, naloxone, pra
109 ultures of rat hepatocytes were treated with lipid emulsions, linoleic or oleic acid, and UCP-2 expre
110 Recently, we have shown that intravenous lipid emulsion (liposyn) infusion during a 120-min eugly
111 riod 2, saline (nicotinic acid [NA], n = 7), lipid emulsion (NA plus lipid emulsion [NAL], n = 8), or
112 c acid [NA], n = 7), lipid emulsion (NA plus lipid emulsion [NAL], n = 8), or glycerol (NA plus glyce
113 l (SMOF) with that of soybean oil (SO)-based lipid emulsion on intrahepatocellular lipid (IHCL) conte
115 g the soybean oil with a parenteral fish-oil lipid emulsion or emulsions of mixed-lipid sources.
116 photericin B delivered as a locally prepared lipid emulsion or in liposomes reduced nephrotoxicity to
117 data to warrant wholesale switching to novel lipid emulsions or the global use of glutamine or growth
118 Here, we infused 20% Intralipid (a synthetic lipid emulsion) or saline intraduodenally for 90 min at
120 -III molecule are critical for attachment to lipid emulsion particles and consequently inhibition of
122 articles (phospholipid unilamellar vesicles, lipid emulsion particles) gave rise to stoichiometric li
124 the unanimous support for the integration of lipid emulsions, particularly those containing fish oil,
126 Mean change in triglycerides was elevated in lipid emulsion patients (61 mg/dL, sd 87) compared with
128 between groups and was 5 mg/dL ( sd 20) for lipid emulsion patients, and 2 mg/dL ( sd 18) for contro
129 data indicate that intraosseous infusion of lipid emulsion rapidly reverses bupivacaine-induced card
130 aining soybean oil-based and olive oil-based lipid emulsion resulted in similar rates of infectious a
132 ajor compositional components of intravenous lipid emulsions routinely administered to preterm infant
133 ding fat administered as a soybean oil-based lipid emulsion (SOLE), is a life-saving therapy but may
136 The next day, the infusate was changed to a lipid emulsion that contained (14C) cholesterol and (3H)
137 rmine whether early initiation of lipids and lipid emulsions that are not purely soybean oil-based re
138 proinflammatory effects of soybean oil-based lipid emulsions, the only Food and Drug Administration-a
139 of a patient successfully resuscitated with lipid emulsion therapy after prolonged and intractable l
140 te a case report involving successful use of lipid emulsion therapy for intractable cardiac arrest du
142 This case demonstrates the need to consider lipid emulsion therapy in the advanced cardiac life supp
144 lation, oxygenation, and chest compressions, lipid emulsion therapy should be a primary element in th
146 standard advanced cardiac life-support (1D), lipid-emulsion therapy (1D), and we suggest venoarterial
147 f myocardial dysfunction is present (2D), IV lipid-emulsion therapy (2D), and using a pacemaker in th
150 ement of intragastric self-administration of lipid emulsions to determine the extent to which postora
151 gies, including modifications of intravenous lipid emulsions to reduce pro-inflammatory fatty acids a
159 We questioned whether the catabolism of lipid emulsions would be changed after enrichment with f